Skip to main content
Log in

Gender Aspects in Cardiovascular Pharmacology

  • Published:
Journal of Cardiovascular Translational Research Aims and scope Submit manuscript

Abstract

The influence of biological sex on pharmacokinetics and pharmacodynamics has been previously described for each step of the metabolic cascade of pharmaceuticals. Women and men display differences in distribution, metabolism, and excretion of drugs for several biologic reasons. Estrogens are relevant in these processes, but cannot be regarded as the only responsible mechanism. Sex differences in the incidence of adverse drug reactions and pharmacotoxicity have also been reported for several classes of drugs and specifically for several cardiovascular preparations. Given the high incidence of cardiovascular conditions and thus the broad use of these drugs in the general population, these reports have to be considered of relevance to public health. Nonetheless, increased knowledge has not translated into the development and implementation of gender-specific pharmacologic guidelines which appear as the only effective strategy to minimize the incidence of sex-specific side effects and adverse drug reactions. In the present review, we analyze the basic aspects of sex-specific pharmacodynamics and present several examples of gender dimorphism in cardiovascular drugs. We also suggest measures to analyze and possibly improve current therapeutic strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Alexander, K. P., Chen, A. Y., Newby, L. K., Schwartz, J. B., Redberg, R. F., Hochman, J. S., et al. (2006). Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative. Circulation, 114(13), 1380–1387.

    Article  PubMed  CAS  Google Scholar 

  2. Anderson, G. D. (2005). Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. Journal of Womens Health, 14(1), 19–29.

    Article  Google Scholar 

  3. Anthony, M. (2005). Male/female differences in pharmacology: safety issues with QT-prolonging drugs. Journal of Womens Health, 14(1), 47–52.

    Article  Google Scholar 

  4. Arias-Loza, P. A., Jazbutyte, V., & Pelzer, T. (2008). Genetic and pharmacologic strategies to determine the function of estrogen receptor alpha and estrogen receptor beta in cardiovascular system. Gender Medicine, 5(Suppl A), S34–S45.

    Article  PubMed  Google Scholar 

  5. Baraona, E., Abittan, C. S., Dohmen, K., Moretti, M., Pozzato, G., Chayes, Z. W., et al. (2001). Gender differences in pharmacokinetics of alcohol. Alcoholism, Clinical and Experimental Research, 25(4), 502–507.

    Article  PubMed  CAS  Google Scholar 

  6. CM, Brinkman-Van der Linden, Havenaar, E. C., Van Ommen, C. R., Van Kamp, G. J., Gooren, L. J., & Van Dijk, W. (1996). Oral estrogen treatment induces a decrease in expression of sialyl Lewis x on alpha 1-acid glycoprotein in females and male-to-female transsexuals. Glycobiology, 6(4), 407–412.

    Article  Google Scholar 

  7. Brown, D. A., Lynch, J. M., Armstrong, C. J., Caruso, N. M., Ehlers, L. B., Johnson, M. S., et al. (2005). Susceptibility of the heart to ischaemia-reperfusion injury and exercise-induced cardioprotection are sex-dependent in the rat. Journal of Physiology, 564(Pt 2), 619–630.

    Article  PubMed  CAS  Google Scholar 

  8. Bruno, R., Vivier, N., Montay, G., Le Liboux, A., Powe, L. K., Delumeau, J. C., et al. (1997). Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis. Clinical Pharmacology and Therapeutics, 62(5), 518–526.

    Article  PubMed  CAS  Google Scholar 

  9. Camper-Kirby, D., Welch, S., Walker, A., Shiraishi, I., Setchell, K. D., Schaefer, E., et al. (2001). Myocardial Akt activation and gender: increased nuclear activity in females versus males. Circulation Research, 88(10), 1020–1027.

    Article  PubMed  CAS  Google Scholar 

  10. Carroll, J. D., Carroll, E. P., Feldman, T., Ward, D. M., Lang, R. M., McGaughey, D., et al. (1992). Sex-associated differences in left ventricular function in aortic stenosis of the elderly. Circulation, 86(4), 1099–1107.

    PubMed  CAS  Google Scholar 

  11. Cerrutti, J. A., Brandoni, A., Quaglia, N. B., & Torres, A. M. (2002). Sex differences in p-aminohippuric acid transport in rat kidney: role of membrane fluidity and expression of OAT1. Molecular and Cellular Biochemistry, 233(1–2), 175–179.

    Article  PubMed  CAS  Google Scholar 

  12. Ciana, P., Raviscioni, M., Mussi, P., Vegeto, E., Que, I., Parker, M. G., et al. (2003). In vivo imaging of transcriptionally active estrogen receptors. Natural Medicines, 9(1), 82–86.

    Article  CAS  Google Scholar 

  13. Drici, M. D., Knollmann, B. C., Wang, W. X., & Woosley, R. L. (1998). Cardiac actions of erythromycin: influence of female sex. JAMA, 280(20), 1774–1776.

    Article  PubMed  CAS  Google Scholar 

  14. Du, X. J. (2004). Gender modulates cardiac phenotype development in genetically modified mice. Cardiovascular Research, 63(3), 510–519.

    Article  PubMed  CAS  Google Scholar 

  15. Edwards, D. P. (2005). Regulation of signal transduction pathways by estrogen and progesterone. Annual Review of Physiology, 67, 335–376.

    Article  PubMed  CAS  Google Scholar 

  16. Ereshefsky, L., Saklad, S. R., Watanabe, M. D., Davis, C. M., & Jann, M. W. (1991). Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. Journal of Clinical Psychopharmacology, 11(5), 296–301.

    Article  PubMed  CAS  Google Scholar 

  17. Fitzgerald, P. T., & Ackerman, M. J. (2005). Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart Rhythm, 2(2 Suppl), S30–S37.

    Article  PubMed  Google Scholar 

  18. Franconi, F., Brunelleschi, S., Steardo, L., & Cuomo, V. (2007). Gender differences in drug responses. Pharmacological Research, 55(2), 81–95.

    Article  PubMed  CAS  Google Scholar 

  19. Frezza, M., di Padova, C., Pozzato, G., Terpin, M., Baraona, E., & Lieber, C. S. (1990). High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. New England Journal of Medicine, 322(2), 95–99.

    Article  PubMed  CAS  Google Scholar 

  20. Gandhi, M., Aweeka, F., Greenblatt, R. M., & Blaschke, T. F. (2004). Sex differences in pharmacokinetics and pharmacodynamics. Annual Review Pharmacology and Toxicology, 44, 499–523.

    Article  CAS  Google Scholar 

  21. Gaudry, S. E., Sitar, D. S., Smyth, D. D., McKenzie, J. K., & Aoki, F. Y. (1993). Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. Clinical Pharmacology and Therapeutics, 54(1), 23–27.

    PubMed  CAS  Google Scholar 

  22. Ghali, J. K., Pina, I. L., Gottlieb, S. S., Deedwania, P. C., & Wikstrand, J. C. (2002). Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation, 105(13), 1585–1591.

    Article  PubMed  CAS  Google Scholar 

  23. Gochfeld, M. (2007). Framework for gender differences in human and animal toxicology. Environmental Research, 104(1), 4–21.

    Article  PubMed  CAS  Google Scholar 

  24. Grohe, C., Kahlert, S., Lobbert, K., & Vetter, H. (1998). Expression of oestrogen receptor alpha and beta in rat heart: role of local oestrogen synthesis. Journal of Endocrinology, 156(2), R1–R7.

    Article  PubMed  CAS  Google Scholar 

  25. Guengerich, F. P. (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annual Review of Pharmacology and Toxicology, 39, 1–17.

    Article  PubMed  CAS  Google Scholar 

  26. Haram, K., Augensen, K., & Elsayed, S. (1983). Serum protein pattern in normal pregnancy with special reference to acute-phase reactants. British Journal of Obstetrics and Gynaecology, 90(2), 139–145.

    PubMed  CAS  Google Scholar 

  27. Humphries, K. H., Kerr, C. R., Connolly, S. J., Klein, G., Boone, J. A., Green, M., et al. (2001). New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation, 103(19), 2365–2370.

    PubMed  CAS  Google Scholar 

  28. Hunt, C. M., Westerkam, W. R., & Stave, G. M. (1992). Effect of age and gender on the activity of human hepatic CYP3A. Biochemical Pharmacology, 44(2), 275–283.

    Article  PubMed  CAS  Google Scholar 

  29. Hutson, W. R., Roehrkasse, R. L., & Wald, A. (1989). Influence of gender and menopause on gastric emptying and motility. Gastroenterology, 96(1), 11–17.

    PubMed  CAS  Google Scholar 

  30. Kadokami, T., McTiernan, C. F., Kubota, T., Frye, C. S., & Feldman, A. M. (2000). Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. Journal of Clinical Investigation, 106(4), 589–597.

    Article  PubMed  CAS  Google Scholar 

  31. Kalow, W., & Tang, B. K. (1991). Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clinical Pharmacology and Therapeutics, 50(5 Pt 1), 508–519.

    PubMed  CAS  Google Scholar 

  32. Kendall, M. J., Quarterman, C. P., Jack, D. B., & Beeley, L. (1982). Metoprolol pharmacokinetics and the oral contraceptive pill. British Journal of Clinical Pharmacology, 14(1), 120–122.

    PubMed  CAS  Google Scholar 

  33. Labbe, L., Sirois, C., Pilote, S., Arseneault, M., Robitaille, N. M., Turgeon, J., et al. (2000). Effect of gender, sex hormones, time variables and physiological urinary pH on apparent CYP2D6 activity as assessed by metabolic ratios of marker substrates. Pharmacogenetics, 10(5), 425–438.

    Article  PubMed  CAS  Google Scholar 

  34. Lan, L. B., Dalton, J. T., & Schuetz, E. G. (2000). Mdr1 limits CYP3A metabolism in vivo. Molecular Pharmacology, 58(4), 863–869.

    PubMed  CAS  Google Scholar 

  35. Lees, J., Hallak, J. E., Deakin, J. F., & Dursun, S. M. (2004). Gender differences and the effects of ketamine in healthy volunteers. Journal of Psychopharmacology, 18(3), 337–339.

    Article  PubMed  CAS  Google Scholar 

  36. Leinwand, L. A. (2003). Sex is a potent modifier of the cardiovascular system. Journal of Clinical Investigation, 112(3), 302–307.

    PubMed  CAS  Google Scholar 

  37. Litwin, S. E., Katz, S. E., Litwin, C. M., Morgan, J. P., & Douglas, P. S. (1999). Gender differences in postinfarction left ventricular remodeling. Cardiology, 91(3), 173–183.

    Article  PubMed  CAS  Google Scholar 

  38. Mahmoodzadeh, S., Eder, S., Nordmeyer, J., Ehler, E., Huber, O., Martus, P., et al. (2006). Estrogen receptor alpha up-regulation and redistribution in human heart failure. FASEB Journal, 20(7), 926–934.

    Article  PubMed  CAS  Google Scholar 

  39. Makkar, R. R., Fromm, B. S., Steinman, R. T., Meissner, M. D., & Lehmann, M. H. (1993). Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA, 270(21), 2590–2597.

    Article  PubMed  CAS  Google Scholar 

  40. Mearadji, B., Penning, C., Vu, M. K., van der Schaar, P. J., van Petersen, A. S., Kamerling, I. M., et al. (2001). Influence of gender on proximal gastric motor and sensory function. American Journal of Gastroenterology, 96(7), 2066–2073.

    Article  PubMed  CAS  Google Scholar 

  41. Mendelsohn, M. E., & Karas, R. H. (1999). The protective effects of estrogen on the cardiovascular system. New England Journal of Medicine, 340(23), 1801–1811.

    Article  PubMed  CAS  Google Scholar 

  42. Mendelsohn, M. E., & Karas, R. H. (2005). Molecular and cellular basis of cardiovascular gender differences. Science, 308(5728), 1583–1587.

    Article  PubMed  CAS  Google Scholar 

  43. Metivier, R., Penot, G., Hubner, M. R., Reid, G., Brand, H., Kos, M., et al. (2003). Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell, 115(6), 751–763.

    Article  PubMed  CAS  Google Scholar 

  44. Mosca, L., Banka, C. L., Benjamin, E. J., Berra, K., Bushnell, C., Dolor, R. J., et al. (2007). Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation, 115(11), 1481–1501.

    Article  PubMed  Google Scholar 

  45. Nordmeyer, J., Eder, S., Mahmoodzadeh, S., Martus, P., Fielitz, J., Bass, J., et al. (2004). Upregulation of myocardial estrogen receptors in human aortic stenosis. Circulation, 110(20), 3270–3275.

    Article  PubMed  CAS  Google Scholar 

  46. Nuedling, S., Karas, R. H., Mendelsohn, M. E., Katzenellenbogen, J. A., Katzenellenbogen, B. S., Meyer, R., et al. (2001). Activation of estrogen receptor beta is a prerequisite for estrogen-dependent upregulation of nitric oxide synthases in neonatal rat cardiac myocytes. FEBS Letters, 502(3), 103–108.

    Article  PubMed  CAS  Google Scholar 

  47. Os, I., Bratland, B., Dahlof, B., Gisholt, K., Syvertsen, J. O., & Tretli, S. (1992). Female sex as an important determinant of lisinopril-induced cough. Lancet, 339(8789), 372.

    Article  PubMed  CAS  Google Scholar 

  48. Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., et al. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine, 341(10), 709–717.

    Article  PubMed  CAS  Google Scholar 

  49. Rathore, S. S., Curtis, J. P., Wang, Y., Bristow, M. R., & Krumholz, H. M. (2003). Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA, 289(7), 871–878.

    Article  PubMed  CAS  Google Scholar 

  50. Rathore, S. S., Wang, Y., & Krumholz, H. M. (2002). Sex-based differences in the effect of digoxin for the treatment of heart failure. New England Journal of Medicine, 347(18), 1403–1411.

    Article  PubMed  CAS  Google Scholar 

  51. Regitz-Zagrosek, V. (2006). Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nature Reviews. Drug Discovery, 5(5), 425–438.

    Article  PubMed  CAS  Google Scholar 

  52. Regitz-Zagrosek, V., Lehmkuhl, E., Lehmkuhl, H. B., & Hetzer, R. (2004). Gender aspects in heart failure. Pathophysiology and medical therapy. Archives Des Maladies Du Coeur Et Des Vaisseaux, 97(9), 899–908.

    PubMed  CAS  Google Scholar 

  53. Ridker, P. M., Cook, N. R., Lee, I. M., Gordon, D., Gaziano, J. M., Manson, J. E., et al. (2005). A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. New England Journal of Medicine, 352(13), 1293–1304.

    Article  PubMed  CAS  Google Scholar 

  54. Rubanyi, G. M., Kauser, K., & Johns, A. (2002). Role of estrogen receptors in the vascular system. Vascular Pharmacology, 38(2), 81–88.

    Article  PubMed  CAS  Google Scholar 

  55. Schmidt, R., Baumann, F., Hanschmann, H., Geissler, F., & Preiss, R. (2001). Gender difference in ifosfamide metabolism by human liver microsomes. European Journal of Drug Metabolism and Pharmacokinetics, 26(3), 193–200.

    PubMed  CAS  Google Scholar 

  56. Schwartz, J. B. (2003). The influence of sex on pharmacokinetics. Clinical Pharmacokinetics, 42(2), 107–121.

    Article  PubMed  CAS  Google Scholar 

  57. Singer, A. J., & Brandt, L. J. (1991). Pathophysiology of the gastrointestinal tract during pregnancy. American Journal of Gastroenterology, 86(12), 1695–1712.

    PubMed  CAS  Google Scholar 

  58. Skaanild, M. T., & Friis, C. (1999). Cytochrome P450 sex differences in minipigs and conventional pigs. Pharmacology and Toxicology, 85(4), 174–180.

    PubMed  CAS  Google Scholar 

  59. Smith, C. L., Conneely, O. M., & O'Malley, B. W. (1993). Modulation of the ligand-independent activation of the human estrogen receptor by hormone and antihormone. Proceedings of the National Academy of Sciences of the United States of America, 90(13), 6120–6124.

    Article  PubMed  CAS  Google Scholar 

  60. Tanaka, E. (1998). Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. Journal of Clinical Pharmacy and Therapeutics, 23(6), 403–416.

    Article  PubMed  CAS  Google Scholar 

  61. Tatchum-Talom, R., Eyster, K. M., & Martin, D. S. (2005). Sexual dimorphism in angiotensin II-induced hypertension and vascular alterations. Canadian Journal of Physiology and Pharmacology, 83(5), 413–422.

    Article  PubMed  CAS  Google Scholar 

  62. Tuck, C. H., Holleran, S., & Berglund, L. (1997). Hormonal regulation of lipoprotein(a) levels: effects of estrogen replacement therapy on lipoprotein(a) and acute phase reactants in postmenopausal women. Arteriosclerosis, Thrombosis, and Vascular Biology, 17(9), 1822–1829.

    PubMed  CAS  Google Scholar 

  63. Walle, T., Walle, K., Mathur, R. S., Palesch, Y. Y., & Conradi, E. C. (1994). Propranolol metabolism in normal subjects: association with sex steroid hormones. Clinical Pharmacology and Therapeutics, 56(2), 127–132.

    PubMed  CAS  Google Scholar 

  64. Weinberg, E. O., Mirotsou, M., Gannon, J., Dzau, V. J., Lee, R. T., & Pratt, R. E. (2003). Sex dependence and temporal dependence of the left ventricular genomic response to pressure overload. Physiological Genomics, 12(2), 113–127.

    PubMed  CAS  Google Scholar 

  65. Wilson, K. (1984). Sex-related differences in drug disposition in man. Clinical Pharmacokinetics, 9(3), 189–202.

    Article  PubMed  CAS  Google Scholar 

  66. Wing, L. M., Reid, C. M., Ryan, P., Beilin, L. J., Brown, M. A., Jennings, G. L., et al. (2003). A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. New England Journal of Medicine, 348(7), 583–592.

    Article  PubMed  CAS  Google Scholar 

  67. Wolbrette, D., Naccarelli, G., Curtis, A., Lehmann, M., & Kadish, A. (2002). Gender differences in arrhythmias. Clinical Cardiology, 25(2), 49–56.

    Article  PubMed  Google Scholar 

  68. Wysowski, D. K., & Swartz, L. (2005). Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002: the importance of reporting suspected reactions. Archives of Internal Medicine, 165(12), 1363–1369.

    Article  PubMed  Google Scholar 

  69. Xin, H. B., Senbonmatsu, T., Cheng, D. S., Wang, Y. X., Copello, J. A., Ji, G. J., et al. (2002). Oestrogen protects FKBP12.6 null mice from cardiac hypertrophy. Nature, 416(6878), 334–338.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The Center for Gender in Medicine is supported by funding from the Deutsche Froschungsgesellschaft, the Ministry of Education and Research, the Ministry of Family Affairs, Senior Citizens, Women and Youth, and the Margarete Ammond Stiftung.

Conflicts of interest

The authors have no conflicts of interest to declare.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Vera Regitz-Zagrosek.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oertelt-Prigione, S., Regitz-Zagrosek, V. Gender Aspects in Cardiovascular Pharmacology. J. of Cardiovasc. Trans. Res. 2, 258–266 (2009). https://doi.org/10.1007/s12265-009-9114-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12265-009-9114-9

Keywords

Navigation